Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Reports Surging Q4 Revenue Amid Increased Net Loss

NEW YORK, Feb. 25 (GenomeWeb News) - CombiMatrix reported yesterday that fourth-quarter revenues surged by around $470,000, but that net loss increased by almost half, the company said.

 

Mulkiteo, Wash.-based CombiMatrix had $522,000 in total revenues for fourth quarter, compared to revenues of  $53,000 for the same quarter last year, while increasing its net loss 44 percent to $1.6 million from $1.1 million in the year-ago period.

 

The life-sciences unit of Acacia Research had research and development expenses of $1.4 million for the quarter, down 27 percent from $1.9 million in the fourth quarter of 2003.

 

CombiMatrix said it had around $23.7 million in cash, equivalents, and short-term investments as of Dec. 31, 2004.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.